OR WAIT null SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
FDA is re-engineering the CMC review process for innovator and generic drugs and backing risk-based ICH quality standards.
Related Content: